China develops Omicron vaccines through multiple technical routes: official
BEIJING, July 23 (Xinhua) -- China is currently conducting monovalent and multivalent vaccine research and development against Omicron variants through multiple technical routes.
Chinese vaccines still protect against severe illness and death caused by Omicron variants, said Feng Zijian, executive vice president and secretary general of the Chinese Preventive Medicine Association. Feng made the remarks at a press conference held by the State Council joint prevention and control mechanism against COVID-19 on Saturday.
The monovalent inactivated vaccines are undergoing clinical trials in Zhejiang, Hunan, and Hong Kong.
The tetravalent recombinant protein vaccines have obtained approved documents for phase III clinical trials in the United Arab Emirates, and relevant studies have been carried out.
China is pushing forward its vaccine research and development against Omicron variants rapidly and steadily, said the official.
Photos
Related Stories
- Smaller Chinese cities battle Omicron resurgence with limited medical resources, financial pressure
- BA.5 Omicron subvariant 4 times more vaccine-resistant: study
- Omicron variant may bring second-largest U.S. COVID wave: The Guardian
- BA.5 becoming dominant Omicron subvariant across the world: health official
- Newer Omicron subvariants account for over 70 pct new infections in U.S.
- Half Canadians infected with Omicron: report
- New Omicron subvariants make up nearly 13 pct new COVID infections in U.S.: CDC
- New Omicron subvariant makes up nearly 60 pct of new U.S. COVID-19 cases
- Philippines detects local transmission of Omicron BA.2.12.1 subvariant
- Health experts back China's COVID-19 control policy
Copyright © 2022 People's Daily Online. All Rights Reserved.
